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Successful Heart and Liver Transplantation in a Swiss Patient With Glu89Lys
Transthyretin Amyloidosis
Transthyretin (TTR) amyloidosis
(MIM 176300) is the most common
form of autosomal dominant hereditary
systemic amyloidosis and causes familial
amyloid polyneuropathy (FAP). TTR is
a plasma transport protein for thyroid
hormone and retinol-binding protein/
vitamin A. More than 100 distinct mu-
tations have been described in the TTR
gene, the Val30Met mutation being the
most common.FAPisaworldwidedisease
with endemic foci inPortugal, Sweden, Ja-
pan, and Brazil. Significant phenotypic
variability is associated with different mu-
tations; it is also observed in patients
harboring the same mutation (1). Initial
presentation is usually a sensory periph-
eral polyneuropathy (PNP), followed by
motor and autonomic impairment. Car-
diac and renal dysfunction may be ob-
served. Carpal tunnel syndrome (CTS)
can be the primary clinical manifestation.
Herein,we report anexceptionalGlu89Lys
TTR mutation in a Swiss family pre-
senting with a severe phenotype char-
acterized by unusually early heart
dysfunction leading to heart and sub-
sequent liver transplantation.
CASE REPORT
A 46-year-old Swiss woman was
investigated for rapid-onset exertion-
induced dyspnoea with generalized edema.
Shehad ahistory of leftCTS treated byme-
dian nerve release at the age of 42 years.
Echocardiographic examination revealed
hypertrophic cardiomyopathy, and sub-
endocardial muscle biopsy revealed amy-
loid deposits (Fig. 1B) of the TTR type.
Other investigations revealed no vitreous
deposits, normal kidney function, and
no paraproteinemia. Small interfascicular
amyloiddepositswereobserved in aquad-
riceps muscle biopsy (Fig. 1C). As cardiac
dysfunctionwasprogressive, aheart trans-
plantwas successfullyperformedat theage
of 49 years. Histologic examination of the
explanted heart confirmed the presence of
extensiveamyloiddeposits (Fig. 1D).After
heart transplantation, the patient reported
increasingpain and loss of sensation in the
feet, slow bowel habit, and delayed urine
flow. On examination, we found ortho-
static hypotension, sensory loss, muscle
weakness, and mild atrophy in the distal
lower extremities with reduced Achilles
tendon reflexes. Nerve conduction stud-
ies revealed amild decrease of amplitude
of motor and sensory action potentials
andnormal velocities except for bilateral
slowing within the carpal tunnels. The
sympathetic skin response to electrical
stimuli was normal in the palms but not
in the soles. The family history was in-
formative with the patient’s mother,
maternal grandmother, and anuncle dy-
ing between the ages of 50 and 55 years
because of cardiac dysfunction (Fig. 1A).
An autopsy of themother showed exten-
sive amyloid deposits, prominently in
the heart muscle. The patient’s daughter
had surgery for bilateral CTS at the age
of 19 years with recurrence of sensory
symptoms 4 years later. Direct DNA se-
quencing of the TTR gene showed a
heterozygous Glu89Lys mutation in the
proband and her daughter. We did not
find any superimposed cause of axonal
polyneuropathy, including diabetes,
hypothyroidism, nutritional factors,
rheumatologic or vasculitic conditions,
M-protein, and infections. Therefore,
the patient was treated with an ortho-
topic liver transplant (OLT) 18 months
after the cardiac transplant and main-
tained on oral cyclosporine and myco-
phenolate mofetil. Although neurologic
examination did not show obvious
changes at 8 months post-OLT, nerve
conduction studies parameters demon-
strated minor worsening of the motor
and sensory neuropathy. No amyloid re-
surgence was demonstrated in the trans-
planted heart using polarized light and
congo-red staining on 23 successive en-
domyocardial biopsies.
e40 | www.transplantjournal.com Transplantation • Volume 91, Number 6, March 27, 2011
DISCUSSION
Our patient presented dramati-
cally with a previously unrecognized
FAP complicated by heart failure requir-
ing heart transplantation. The neuro-
logic disorder was identified late, based
on history of CTS, painful PNP, and dy-
sautonomic features. In the only pre-
viously reported Glu89Lys TTR FAP
patient (an unrelated American pa-
tient), presentation was with an early
painful PNP with hypertrophic car-
diomyopathy that developed 6 years
later, eventually leading to combined
heart and liver transplants (2). Ac-
cording to the FAP World Transplant
Registry, among 575 reported trans-
plants, only 6 were combined liver and
heart transplants (3). Cardiovascular
symptoms are reported to be less re-
sponsive to OLT and account for 39%
of post-OLT deaths, mainly due to
progressive amyloid heart deposits of
wild-type TTR from the donor liver
(4). Unlike the reported stabilization
or improvement (3, 4), the patient’s
neuropathy slightly worsened after
OLT. The cause of this worsening re-
mains uncertain given that the patient
developed concomitant steroid-induced
diabetes. We found a high phenotypic
penetrance in this Glu89Lys family
with an onset between the ages of 20
and 45 years, but contrary to Val30Met
FAP, we failed to find anticipation
with maternal inheritance (5). Our re-
port underlines the importance of
TTR mutation screening in FAP to en-
sure adequate patient follow-up and
for prognostic purposes, especially in
relation to cardiac involvement with
the Glu89Lys mutation. Regular car-
diac evaluations will be undertaken for
the youngest carrier who is in good
health at the present time.
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FIGURE 1. Family pedigree of Glu89Lys-mutated patients and results of tissue biopsies. (A) The index case appears with
arrowhead; hallmarks are given for those family members with proven amyloidosis (autopsy or biopsy), Glu89Lys geno-
type, cardiac or neurologic manifestations. (B) Pretransplant subendocardial biopsy, demonstrating deposits of amyloid
between cardiomyocytes; congo-red staining, asterisk. (C) Quadriceps muscle biopsy showing amyloid deposits between
muscle fibers; congo-red staining, arrows. (D) Explanted heart showing marked interstitial amyloid deposits; transthyretin
immunostaining, asterisk.
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Maximizing Use of Marginal Liver Grafts for Transplantation: A Case Report
of Absent Donor Extrahepatic Portal Vein
Absence of the portal vein because
of atrophy, agenesis, or aplasia can lead
to both end-stage liver disease and he-
patic tumors and therefore can be an in-
dication for transplantation. We report
the case of a successfully transplanted
graft froma recipientwith absence of the
extrahepatic portal venous system. This
situation has never been previously de-
scribed in the literature.
CASE REPORT
This donor, deceased after brain
death, was a 45-year-old woman who
died from a subarachnoid hemorrhage.
Her medical history included a splenec-
tomy at the age of 10 years (reason not
known), an aneurysm clipped at the age
of 15 years, and a laparotomy at the age
of 21 years for a traumatic perforated
stomach and intestine after a road traffic
accident. She also had undergone a cae-
sarian section at the age of 32 years after
which she was jaundiced and a cholecys-
tectomy at the age of 42 years. Just before
organ donation, her liver function tests
were normal.
The liver appearance was normal.
However, during liver retrieval, it was
noted that the extrahepatic portal vein
was not present. A large-diameter com-
mon hepatic artery was identified. No
difficulty was encountered in dissecting
the porta because of collaterals. The
pancreas was not retrieved.
Back-table dissection of the liver
confirmed normal anatomy except for
the absence of the extrahepatic portal
vein to the level of the hilar plate. Portal
vein collaterals were found and could
be traced to a bifurcation into the left
and right intrahepatic portal venous
systems. Donor iliac vein was anasto-
mosed to the intrahepatic portal vein
bifurcation on the back table, and an
angiogram was performed on the
bench (Fig. 1a).
The recipient was a 68-year-old
woman with primary biliary cirrhosis.
Model for end-stage liver disease score
was18. The portal vein was patent. The
donor portal venous anomaly and
the absence of guiding medical litera-
ture were explained to the patient. Af-
ter this, the patient elected to undergo
transplantation.
The allograft was implanted using
a side-to-side cavocavostomy with tem-
porary portocaval shunt. Initial reperfu-
sion followed arterial reconstruction.
Reperfusion was tolerated, and liver ap-
pearance was satisfactory. The reconsti-
tuted donor vein was anastomosed in an
end-to-end fashion to the patent recipi-
ent portal vein. A duct-to-duct biliary
anastomosis was performed.
A postoperative computed to-
mography scan with vascular recon-
struction demonstrates the transplanted
hepatic vascular anatomy (Fig. 1b). Her
alanine aminotransferase peaked at 1082
on day 2 and decreased to 155 by day 10.
However, alanine aminotransferase be-
gan to increase leading to a liver biopsy
on day 13. This demonstrated acute cel-
lular rejection, treated withmethylpred-
nisolone. The recipient has now been
followed up for 4 years, and computed
tomography scan confirms patency of
the portal vein. Recurrent PBC has been
confirmed by liver biopsy although she
remains well with good liver function.
DISCUSSION
There are no previous reports of a
liver with portal vein atrophy being
transplanted. A possible explanation for
the absence of an extrahepatic portal
system seen in this donor is previous
portal vein thrombosis. This is the likely
explanation given her medical history.
Alternatively, it could be due to a
true congenital abnormality. This is a
rare condition in which the enteric
blood bypasses the liver and drains di-
rectly into the systemic circulation. It
can be subdivided into type 1 with no
portal vein perfusion to the liver and
type 2 where there remains a degree of
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